Latest Kaiser Health News Stories
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
The state’s governor said the plan has the full support of the White House. But the Trump administration was noncommittal about whether allowing states to buy and import cheaper drugs from up north could be the answer to the nation’s drug-pricing problem.
Most hearings before the U.S. House and Senate are routine affairs. But a few tense moments featuring everyone from Hillary Clinton to tobacco CEOs drew the attention of millions of Americans.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
Medicare and many private insurers view prescribing drugs to improve sexual function as a lifestyle issue that’s not medically necessary to pay for.
Unwilling to wait for federal action, California Gov. Gavin Newsom says he has a plan that could extract discounts from drugmakers and save the state money — one he hopes other states can join.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Health was a featured player in President Donald Trump’s 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current “Bill of the Month” feature.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
The president laid out a series of goals, including lowering prescription prices, pursuing an end to the HIV epidemic and boosting funding for childhood cancers.
The White House and HHS want to eliminate a “shadowy system of kickbacks” in the drug industry pipeline.
Congress and President Donald Trump are starting to wrestle with health policy issues, and health is already a key debate point in the early run-up to the 2020 Democratic presidential primaries. Might any major health policy legislation be passed and signed this year? Joanne Kenen of Politico, Anna Edney of Bloomberg News and Kimberly Leonard of The Washington Examiner, along with special guest Tom Miller of the American Enterprise Institute, join KHN’s Julie Rovner to discuss these issues and take questions from a live studio audience.